Natalizumab treatment reduces fatigue in multiple sclerosis. Results from the TYNERGY trial; a study in the real life setting.

Natalizumab treatment reduces fatigue in multiple sclerosis. Results from the TYNERGY trial; a study in the real life setting.

Fatigue is a significant symptom in multiple sclerosis (MS) patients. First-generation disease modifying therapies (DMTs) are at best moderately effective to improve fatigue. Observations from small cohorts have indicated that natalizumab, an antibody targeting VLA-4, may reduce MS-related fatigue....

Full description

Bibliographic Details
Main Authors: Anders Svenningsson, Eva Falk, Elisabeth G Celius, Siegrid Fuchs, Karen Schreiber, Sara Berkö, Jennifer Sun, Iris-Katharina Penner, Tynergy Trial Investigators
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3605436?pdf=render

Internet

http://europepmc.org/articles/PMC3605436?pdf=render

Similar Items